JP2003514808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514808A5 JP2003514808A5 JP2001538892A JP2001538892A JP2003514808A5 JP 2003514808 A5 JP2003514808 A5 JP 2003514808A5 JP 2001538892 A JP2001538892 A JP 2001538892A JP 2001538892 A JP2001538892 A JP 2001538892A JP 2003514808 A5 JP2003514808 A5 JP 2003514808A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- branched
- partially
- twenty
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 99
- -1 prinyl Chemical group 0.000 description 98
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
- 125000003545 alkoxy group Chemical group 0.000 description 26
- 229910052717 sulfur Inorganic materials 0.000 description 23
- 125000004076 pyridyl group Chemical group 0.000 description 21
- 125000001624 naphthyl group Chemical group 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 12
- 125000002883 imidazolyl group Chemical group 0.000 description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 10
- 125000000168 pyrrolyl group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000003373 pyrazinyl group Chemical group 0.000 description 9
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000003226 pyrazolyl group Chemical group 0.000 description 8
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000002098 pyridazinyl group Chemical group 0.000 description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 5
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 5
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000005494 pyridonyl group Chemical group 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 description 3
- ZGXFVYOWURGVSM-UHFFFAOYSA-N 4-[4-(2-morpholin-4-yl-2-thiomorpholin-4-ylthiomorpholin-4-yl)sulfinyl-2-thiomorpholin-4-ylthiomorpholin-2-yl]morpholine Chemical compound C1CSC(N2CCSCC2)(N2CCOCC2)CN1S(=O)N(C1)CCSC1(N1CCSCC1)N1CCOCC1 ZGXFVYOWURGVSM-UHFFFAOYSA-N 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000002933 cyclohexyloxy group Chemical class C1(CCCCC1)O* 0.000 description 3
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000005241 heteroarylamino group Chemical group 0.000 description 3
- 125000005553 heteroaryloxy group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- NNLBRYQGMOYARS-UHFFFAOYSA-N thiane 1-oxide Chemical compound O=S1CCCCC1 NNLBRYQGMOYARS-UHFFFAOYSA-N 0.000 description 3
- ZQKVJTVUSZBVQO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylphenyl)-3-(4-pyridin-3-yloxynaphthalen-1-yl)urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC1=CC=CN=C1 ZQKVJTVUSZBVQO-UHFFFAOYSA-N 0.000 description 2
- WQCKNOHLEAQFAP-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylphenyl)-3-(4-pyridin-4-yloxynaphthalen-1-yl)urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC1=CC=NC=C1 WQCKNOHLEAQFAP-UHFFFAOYSA-N 0.000 description 2
- ZFKFZYAWPJMVGZ-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylphenyl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ZFKFZYAWPJMVGZ-UHFFFAOYSA-N 0.000 description 2
- XXHQUBQLTYBRTG-UHFFFAOYSA-N 1-(5-tert-butyl-2-morpholin-4-ylphenyl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1NC(=O)NC1=CC(C(C)(C)C)=CC=C1N1CCOCC1 XXHQUBQLTYBRTG-UHFFFAOYSA-N 0.000 description 2
- QYCGBAJADAGLLK-UHFFFAOYSA-N 1-(cyclohepten-1-yl)cycloheptene Chemical group C1CCCCC=C1C1=CCCCCC1 QYCGBAJADAGLLK-UHFFFAOYSA-N 0.000 description 2
- VSIYJQNFMOOGCU-UHFFFAOYSA-N 1-(cyclohexen-1-yl)cyclohexene Chemical group C1CCCC(C=2CCCCC=2)=C1 VSIYJQNFMOOGCU-UHFFFAOYSA-N 0.000 description 2
- XVLWJROIONAKQB-UHFFFAOYSA-N 1-[3-bromo-5-tert-butyl-2-(2-morpholin-4-ylethylamino)phenyl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1NC(=O)NC1=CC(C(C)(C)C)=CC(Br)=C1NCCN1CCOCC1 XVLWJROIONAKQB-UHFFFAOYSA-N 0.000 description 2
- MGKPCLNUSDGXGT-UHFFFAOYSA-N 1-benzofuran-3-one Chemical compound C1=CC=C2C(=O)COC2=C1 MGKPCLNUSDGXGT-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- DKROPLKBDHUKRT-UHFFFAOYSA-N 1-[4-(2-aminopyridin-4-yl)oxynaphthalen-1-yl]-3-(5-tert-butyl-2-methylphenyl)urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N)=C1 DKROPLKBDHUKRT-UHFFFAOYSA-N 0.000 description 1
- NZUUXQSBKZPFKK-UHFFFAOYSA-N 4-piperazin-1-ylmorpholine Chemical compound C1CNCCN1N1CCOCC1 NZUUXQSBKZPFKK-UHFFFAOYSA-N 0.000 description 1
- KQTGCJMBUBYSLL-UHFFFAOYSA-N 4-piperidin-1-ylmorpholine Chemical compound C1CCCCN1N1CCOCC1 KQTGCJMBUBYSLL-UHFFFAOYSA-N 0.000 description 1
- SSXTZEGNWOYWNY-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-cyclohepta[b]pyrazine Chemical compound C1CCCCC2=NC=CN=C21 SSXTZEGNWOYWNY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JPZCTPYNLCZLQB-UHFFFAOYSA-N CC(=O)NC1=C(C(=CC(=C1)C(C)(C)C)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24)OC Chemical compound CC(=O)NC1=C(C(=CC(=C1)C(C)(C)C)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24)OC JPZCTPYNLCZLQB-UHFFFAOYSA-N 0.000 description 1
- DQXOHEONGSWKRM-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N(C)C)OC)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N(C)C)OC)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24 DQXOHEONGSWKRM-UHFFFAOYSA-N 0.000 description 1
- VGXRGIMBBBUPCJ-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N2CCOCC2)OC)NC(=O)NC3C(=CC4=CC=NC=C4)C=CC5=CC=CC=C35 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N2CCOCC2)OC)NC(=O)NC3C(=CC4=CC=NC=C4)C=CC5=CC=CC=C35 VGXRGIMBBBUPCJ-UHFFFAOYSA-N 0.000 description 1
- RVYCZCKPTXJYGZ-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 RVYCZCKPTXJYGZ-UHFFFAOYSA-N 0.000 description 1
- HJGYWSBTOJFHEK-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)NC)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)NC)C4=CC=CC=C24 HJGYWSBTOJFHEK-UHFFFAOYSA-N 0.000 description 1
- IOUUKLOBUSZXNL-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 IOUUKLOBUSZXNL-UHFFFAOYSA-N 0.000 description 1
- HMOJKZVAYIDXRR-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=C)NC=C3)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=C)NC=C3)C4=CC=CC=C24 HMOJKZVAYIDXRR-UHFFFAOYSA-N 0.000 description 1
- HNNCJPPPIVJDRG-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 HNNCJPPPIVJDRG-UHFFFAOYSA-N 0.000 description 1
- KZBTYTJSQCUCCE-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(N=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(N=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 KZBTYTJSQCUCCE-UHFFFAOYSA-N 0.000 description 1
- RRCDKJIRBWEMIT-UHFFFAOYSA-N CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(C(=CC(=C5)C(C)(C)C)OC)OC Chemical compound CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(C(=CC(=C5)C(C)(C)C)OC)OC RRCDKJIRBWEMIT-UHFFFAOYSA-N 0.000 description 1
- UWVJQHGDCLERCS-UHFFFAOYSA-N CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(N=CC(=C5)C(C)(C)C)OC Chemical compound CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(N=CC(=C5)C(C)(C)C)OC UWVJQHGDCLERCS-UHFFFAOYSA-N 0.000 description 1
- KJIXACNTXVJWGL-UHFFFAOYSA-N CC1=C(C=C(C=C1)C(C)(C)C)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 Chemical compound CC1=C(C=C(C=C1)C(C)(C)C)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 KJIXACNTXVJWGL-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 206010051920 Glomerulonephropathy Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 125000003113 cycloheptyloxy group Chemical class C1(CCCCCC1)O* 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16590399P | 1999-11-16 | 1999-11-16 | |
| US60/165,903 | 1999-11-16 | ||
| PCT/US2000/031582 WO2001036403A1 (en) | 1999-11-16 | 2000-11-16 | Urea derivatives as anti-inflammatory agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003514808A JP2003514808A (ja) | 2003-04-22 |
| JP2003514808A5 true JP2003514808A5 (enExample) | 2008-01-10 |
| JP4955171B2 JP4955171B2 (ja) | 2012-06-20 |
Family
ID=22600951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538892A Expired - Lifetime JP4955171B2 (ja) | 1999-11-16 | 2000-11-16 | 抗炎症剤としての尿素誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6492393B1 (enExample) |
| EP (1) | EP1232150B1 (enExample) |
| JP (1) | JP4955171B2 (enExample) |
| AT (1) | ATE375334T1 (enExample) |
| AU (1) | AU1617901A (enExample) |
| CA (1) | CA2389360C (enExample) |
| DE (1) | DE60036726T2 (enExample) |
| ES (1) | ES2292488T3 (enExample) |
| MX (2) | MXPA02004594A (enExample) |
| WO (1) | WO2001036403A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2224462T3 (es) * | 1997-12-11 | 2005-03-01 | Janssen Pharmaceutica N.V. | Anilidas mimeticas del acido retinoico. |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| CA2378291A1 (en) * | 1999-07-07 | 2001-01-18 | Astrazeneca Uk Limited | Quinazoline derivatives |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| EP1506962B1 (en) | 2000-10-20 | 2008-07-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic heterocycles |
| US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| US6962926B2 (en) | 2001-01-31 | 2005-11-08 | Telik, Inc. | Antagonist of MCP-1 function, and compositions and methods of use thereof |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| JP2004530690A (ja) * | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| WO2002096876A1 (en) * | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| ATE338035T1 (de) | 2001-06-05 | 2006-09-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen |
| ATE360417T1 (de) | 2001-07-11 | 2007-05-15 | Boehringer Ingelheim Pharma | Methode zur behandlung von zytokinvermittelten erkrankungen |
| US6825184B2 (en) | 2001-10-18 | 2004-11-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-Disubstituted benzo-fused urea compounds |
| US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| SI1580188T1 (sl) | 2002-02-11 | 2012-02-29 | Bayer Healthcare Llc | Aril sečnine kot kinazni inhibitorji |
| WO2003072569A1 (en) * | 2002-02-25 | 2003-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| ATE349210T1 (de) | 2002-07-09 | 2007-01-15 | Boehringer Ingelheim Pharma | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
| AU2003257991A1 (en) | 2002-08-08 | 2004-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| EP1556047A4 (en) * | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| WO2004078746A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1608639A2 (en) | 2003-02-28 | 2005-12-28 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| US7078419B2 (en) * | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| EP1626714B1 (en) | 2003-05-20 | 2007-07-04 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| BRPI0507198A (pt) * | 2004-01-30 | 2007-06-26 | Merck Patent Gmbh | derivados de bisariluréia |
| WO2005110994A2 (en) * | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| AU2011253934C1 (en) * | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| AU2005264988B2 (en) | 2004-06-17 | 2011-09-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| AU2005293839B2 (en) * | 2004-10-13 | 2012-08-23 | Merck Patent Gmbh | Heterocyclic substituted bisarylurea derivatives as kinase inhibitors |
| CN102161653A (zh) * | 2004-11-24 | 2011-08-24 | 雅培制药有限公司 | 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途 |
| US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US7741479B2 (en) | 2004-12-07 | 2010-06-22 | Locus Pharmaceuticals, Inc. | Urea inhibitors of MAP kinases |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| JP2009522363A (ja) * | 2006-01-04 | 2009-06-11 | ローカス ファーマシューティカルズ、インク． | プロテインキナーゼの阻害剤 |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| WO2011109441A1 (en) * | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
| MX2013009931A (es) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Agentes terapeuticos contra tumores. |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| EP2763984B1 (en) | 2011-10-03 | 2016-04-20 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| NZ631388A (en) | 2012-03-28 | 2016-01-29 | Neuropore Therapies Inc | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| BR112015024678B1 (pt) | 2013-04-02 | 2023-02-23 | Oxular Acquisitions Limited | Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| JP6514703B2 (ja) * | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| TWI664967B (zh) | 2014-02-14 | 2019-07-11 | 英商瑞斯比維特有限公司 | 新穎化合物（一） |
| CN113683564A (zh) | 2014-08-28 | 2021-11-23 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| MA40775A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| CA2978226C (en) | 2015-03-04 | 2025-02-18 | Eisai R&D Management Co., Ltd. | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER |
| WO2016171142A1 (ja) | 2015-04-20 | 2016-10-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
| RU2718048C2 (ru) | 2015-08-20 | 2020-03-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| CA3015978A1 (en) | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| WO2018074461A1 (ja) | 2016-10-18 | 2018-04-26 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2018147275A1 (ja) | 2017-02-08 | 2018-08-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| CN110028444B (zh) * | 2019-05-28 | 2022-02-11 | 沈阳药科大学 | 1-芳基-3-[4-(吡啶-2-基甲氧基)苯基]脲类化合物及应用 |
| JP2022151436A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 髄膜炎と脳炎の治療薬。 |
| CN116354891B (zh) * | 2022-11-07 | 2025-01-07 | 河南省锐达医药科技有限公司 | 一种萘基苯醚类化合物、其制备方法及应用 |
| PL248268B1 (pl) * | 2023-04-13 | 2025-11-17 | Uniwersytet Medyczny W Lublinie | 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie |
| CN116987041A (zh) * | 2023-08-02 | 2023-11-03 | 河北科技大学 | 一种转移氢化法制备5-(2-氨基-4-氯苯基)四氮唑的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU185294B (en) | 1980-12-29 | 1984-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing substituted urea derivatives |
| US4423126A (en) * | 1982-05-27 | 1983-12-27 | Eastman Kodak Company | Color-forming carboxamidonaphthalene dye precursor and carboximide dye in photographic material and process |
| GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
| GB8908869D0 (en) | 1989-04-19 | 1989-06-07 | Shell Int Research | A process for the preparation of aromatic ureas |
| WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
| US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| US6001860A (en) | 1992-05-28 | 1999-12-14 | Pfizer Inc. | N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT) |
| GB9302275D0 (en) | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
| US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
| EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| GB9511355D0 (en) * | 1995-06-06 | 1995-08-02 | Fujisawa Pharmaceutical Co | Urea derivatives |
| JPH11514651A (ja) | 1995-10-31 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 置換ピリジルピロール、前記化合物を含む組成物及び使用方法 |
| US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| DE19631303C2 (de) | 1996-08-02 | 1998-07-02 | Kettner Karl Ulrich Prof Dr | Vorrichtung zum Schutz von Gefäßen bei chirurgischen Eingriffen |
| AU7526798A (en) * | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| DE69826695T2 (de) | 1997-05-23 | 2006-02-02 | Bayer Pharmaceuticals Corp., West Haven | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
| JP2001512727A (ja) * | 1997-08-09 | 2001-08-28 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ−１受容体のリガンドとしてのニ環式化合物 |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| JP2001521934A (ja) * | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
| ES2224462T3 (es) * | 1997-12-11 | 2005-03-01 | Janssen Pharmaceutica N.V. | Anilidas mimeticas del acido retinoico. |
| DK1047418T3 (da) * | 1997-12-22 | 2005-11-21 | Bayer Pharmaceuticals Corp | Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer |
| DK1043995T3 (da) * | 1997-12-22 | 2007-03-05 | Bayer Pharmaceuticals Corp | Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer |
| CA2315715C (en) * | 1997-12-22 | 2010-06-22 | Bayer Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| CA2315720A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| KR100320102B1 (ko) | 1998-11-21 | 2002-04-22 | 김원대 | 수직배향된나선변형강유전성액정표시장치 |
| US6166028A (en) * | 1998-12-09 | 2000-12-26 | American Home Products Corporation | Diaminopuridine-containing thiourea inhibitors of herpes viruses |
| EP1163236B1 (en) * | 1999-03-12 | 2005-11-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| ID30176A (id) * | 1999-03-12 | 2001-11-08 | Boehringer Ingelheim Pharma | Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi |
| EP1200411B1 (en) * | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| DE19934321A1 (de) * | 1999-07-21 | 2001-01-25 | Bayer Ag | Naphthyl-substituierte Sulfonamide |
-
2000
- 2000-11-16 CA CA002389360A patent/CA2389360C/en not_active Expired - Lifetime
- 2000-11-16 DE DE60036726T patent/DE60036726T2/de not_active Expired - Lifetime
- 2000-11-16 ES ES00978751T patent/ES2292488T3/es not_active Expired - Lifetime
- 2000-11-16 AU AU16179/01A patent/AU1617901A/en not_active Abandoned
- 2000-11-16 MX MXPA02004594A patent/MXPA02004594A/es active IP Right Grant
- 2000-11-16 MX MXPA02004879A patent/MXPA02004879A/es unknown
- 2000-11-16 JP JP2001538892A patent/JP4955171B2/ja not_active Expired - Lifetime
- 2000-11-16 AT AT00978751T patent/ATE375334T1/de active
- 2000-11-16 EP EP00978751A patent/EP1232150B1/en not_active Expired - Lifetime
- 2000-11-16 WO PCT/US2000/031582 patent/WO2001036403A1/en not_active Ceased
- 2000-11-16 US US09/714,539 patent/US6492393B1/en not_active Expired - Lifetime
-
2002
- 2002-10-15 US US10/271,301 patent/US7241758B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514808A5 (enExample) | ||
| JP2004531571A5 (enExample) | ||
| JP2002539198A5 (enExample) | ||
| JP4955171B2 (ja) | 抗炎症剤としての尿素誘導体 | |
| JP2005503400A5 (enExample) | ||
| JP2002539206A5 (enExample) | ||
| RU2004133034A (ru) | Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38 | |
| JP4820488B2 (ja) | 抗炎症薬として有用な化合物 | |
| US7211575B2 (en) | Methods of treating cytokine mediated diseases | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| JP2005518447A5 (enExample) | ||
| CA2446193A1 (en) | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | |
| JP2004536845A5 (enExample) | ||
| RU2001126337A (ru) | Соединения, пригодные в качестве противовоспалительных агентов | |
| CA2352524A1 (en) | Aromatic heterocyclic compounds as antiinflammatory agents | |
| JP2004534787A5 (enExample) | ||
| US20040110755A1 (en) | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions | |
| RU2004132847A (ru) | Способ лечения гиперсекреции слизи | |
| US20040033222A1 (en) | Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors | |
| AU2004200240B2 (en) | Compounds useful as anti-inflammatory agents | |
| RU2004121842A (ru) | Соединения, пригодные в качестве противовоспалительных агентов | |
| ZA200107446B (en) | Compounds useful as anti-inflammatory agents. | |
| JPS6222748A (ja) | 含窒素テルペンアルコ−ル類及びこれを有効成分とする抗アレルギ−剤 |